The Parties Agree
An agreement on transfer of production of Noltec (ilaprazole), a drug for treatment of gastric and duodenal ulcer, erosive esophagitis and gastroesophageal reflux disease was signed at the Eastern Economic Forum in Vladivostok between R-Pharm group of companies and a South-Korean Il-Yang Pharmaceutical. The drug with significant and long-lasting effect, helps heal ulcers and improves symptoms of the disease.
According to the document signed by Alexey Repik, Chairman of R-Pharm Group, and by Don Yon-Kim, President of Il-Yang Pharmaceutical (South Korea), the Russian company received from the South Korean partner an exclusive license for technology and production of NOLTEC (Ilaprazole) and the rights for marketing in Russia, Belarus and Armenia.
Manufacture of Noltec will be launched at the company site in the Yaroslavl region. The active substance of ilaprazole at the initial stage will be imported to Russia from Korea.